Brief Report: Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Participants With Preexisting K65R/N in HIV-1 in Phase 2/3/3b Clinical Trials
Despite the presence of the TFV signature resistance mutation K65R/N, participants receiving B/F/TAF maintained virologic suppression demonstrating the efficacy of B/F/TAF in this population.
Authors
- Michelle L. D’Antoni (ORCID: https://orcid.org/0009-0004-5395-7022)
- Silvia D. Chang (ORCID: https://orcid.org/0000-0002-9201-8114)
- Archana V. Boopathy (ORCID: https://orcid.org/0009-0009-9164-0858)
- Kristen Andreatta
- Jason T. Hindman (ORCID: https://orcid.org/0000-0003-1513-3423)
- Christian Callebaut (ORCID: https://orcid.org/0000-0003-4721-2572)
Institutions
- Petra Christian University (ID)
- Gilead Sciences (United States) (US)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1097/qai.0000000000003742
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00